Author: admin

  • John Lennon’s killer denied parole for 14th time | John Lennon

    John Lennon’s killer denied parole for 14th time | John Lennon

    The man who killed John Lennon outside the former Beatle’s Manhattan apartment building in 1980 has been denied parole for a 14th time, according to New York prison officials.

    Mark David Chapman, 70, appeared before a parole board on 27 August, and the decision was recently posted online by the state department of corrections and community supervision.

    Chapman fatally shot Lennon on the night of 8 December 1980, as the musician and his wife, Yoko Ono, were returning to their Upper West Side apartment. Lennon had signed an autograph for Chapman on a copy of his recently released album, Double Fantasy, earlier that day.

    Chapman was arrested within minutes, sitting near the shooting scene with a copy of JD Salinger’s novel, The Catcher in the Rye.

    Lennon was 40 years old.

    Mark David Chapman. Photograph: AP

    The transcript for the latest parole board hearing was not immediately available. But Chapman previously expressed remorse for the crime.

    “I knew what I was doing, and I knew it was evil, I knew it was wrong, but I wanted the fame so much that I was willing to give everything and take a human life,” he told a parole board three years ago.

    Chapman is serving a 20-years-to-life sentence at Green Haven correctional facility, north of New York City, according to online state corrections records.

    His next parole hearing is in February 2027.

    Continue Reading

  • Hansoh Pharma in HK$3.9 Billion Share Placement | News

    Hansoh Pharma in HK$3.9 Billion Share Placement | News

    Cleary Gottlieb represented Hansoh Pharmaceutical Group Company Limited (03692.HK) (Hansoh Pharma) in a HK$3.9 billion (approximately $500 million) primary placement through the issuance of 108 million new shares.

    Citigroup Global Markets Limited and Morgan Stanley Asia Limited acted as placing agents and overall coordinators in the placement.

    The placing agreement was signed on August 20, 2025, and the placement closed on August 27, 2025.

    Hansoh Pharma is a leading innovation-driven pharmaceutical enterprise in China, focusing on major disease therapeutic areas such as oncology, anti-infectives, central nervous system, metabolism, and autoimmunity.

    Continue Reading

  • Molecular subtypes of human skeletal muscle in cancer cachexia

    Molecular subtypes of human skeletal muscle in cancer cachexia

  • Xia, L. et al. Sarcopenia and adverse health-related outcomes: an umbrella review of meta-analyses of observational studies. Cancer Med 9, 7964–7978 (2020).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Anoveros-Barrera, A. et al. Clinical and biological characterization of skeletal muscle tissue biopsies of surgical cancer patients. J. Cachexia Sarcopenia Muscle 10, 1356–1377 (2019).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Chalise, P. & Fridley, B. L. Integrative clustering of multi-level ‘omic data based on non-negative matrix factorization algorithm. PLoS ONE 12, e0176278 (2017).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Roeland, E. J. et al. Weight loss versus muscle loss: re-evaluating inclusion criteria for future cancer cachexia interventional trials. Support. Care Cancer 25, 365–369 (2017).

    PubMed 

    Google Scholar 

  • Martin, L. et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J. Clin. Oncol. 31, 1539–1547 (2013).

    Article 
    PubMed 

    Google Scholar 

  • Stretch, C. et al. Effects of sample size on differential gene expression, rank order and prediction accuracy of a gene signature. PLoS ONE 8, e65380 (2013).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Talbert, E. E. et al. Modeling human cancer-induced cachexia. Cell Rep. 28, 1612–1622.e1614 (2019).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Narasimhan, A. et al. Profiling of adipose and skeletal muscle in human pancreatic cancer cachexia reveals distinct gene profiles with convergent pathways. Cancers 13, 1975 (2021).

  • Baracos, V. E., Martin, L., Korc, M., Guttridge, D. C. & Fearon, K. C. H. Cancer-associated cachexia. Nat. Rev. Dis. Primers 4, 17105 (2018).

    Article 
    PubMed 

    Google Scholar 

  • Zhao, K. et al. Transcriptomic signature of cancer cachexia by integration of machine learning, literature mining and meta-analysis. Comput. Biol. Med. 172, 108233 (2024).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Brunet, J. P., Tamayo, P., Golub, T. R. & Mesirov, J. P. Metagenes and molecular pattern discovery using matrix factorization. Proc. Natl Acad. Sci. USA 101, 4164–4169 (2004).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Carmona-Saez, P., Pascual-Marqui, R. D., Tirado, F., Carazo, J. M. & Pascual-Montano, A. Biclustering of gene expression data by non-smooth non-negative matrix factorization. BMC Bioinformatics 7, 78 (2006).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Martin, L. et al. Diagnostic criteria for the classification of cancer-associated weight loss. J. Clin. Oncol. 33, 90–99 (2015).

    Article 
    PubMed 

    Google Scholar 

  • Zhong, X. & Zimmers, T. A. Sex differences in cancer cachexia. Curr. Osteoporos. Rep. 18, 646–654 (2020).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Fearon, K. et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 12, 489–495 (2011).

    Article 
    PubMed 

    Google Scholar 

  • Folker, E. S. & Baylies, M. K. Nuclear positioning in muscle development and disease. Front. Physiol. 4, 363 (2013).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Tay, Y., Rinn, J. & Pandolfi, P. P. The multilayered complexity of ceRNA crosstalk and competition. Nature 505, 344–352 (2014).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Aouci, R. et al. The antidepressant action of fluoxetine involves the inhibition of Dlx5/6 in cortical GABAergic neurons through a TrkB-dependent pathway. Cells 13, 1262 (2024).

  • Lu, Y. et al. The NF-κB-responsive long noncoding RNA FIRRE regulates posttranscriptional regulation of inflammatory gene expression through interacting with hnRNPU. J. Immunol. 199, 3571–3582 (2017).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Li, D. et al. MicroRNAs hsa-miR-495-3p and hsa-miR-486-5p suppress basal and rifampicin-induced expression of human sulfotransferase 2A1 (SULT2A1) by facilitating mRNA degradation. Biochem. Pharmacol. 169, 113617 (2019).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Lecker, S. H. et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J. 18, 39–51 (2004).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Peris-Moreno, D., Cussonneau, L., Combaret, L., Polge, C. & Taillandier, D. Ubiquitin ligases at the heart of skeletal muscle atrophy control. Molecules 26, 407 (2021).

  • Almasud, A. A. et al. Fish oil mitigates myosteatosis and improves chemotherapy efficacy in a preclinical model of colon cancer. PLoS ONE 12, e0183576 (2017).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Neyroud, D. et al. Local inflammation precedes diaphragm wasting and fibrotic remodelling in a mouse model of pancreatic cancer. J. Cachexia Sarcopenia Muscle 16, e13668 (2025).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Spadafora, V. et al. Optimization of a mouse model of pancreatic cancer to simulate the human phenotypes of metastasis and cachexia. BMC Cancer 24, 414 (2024).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Chen, R., Lei, S., Jiang, T., She, Y. & Shi, H. Regulation of skeletal muscle atrophy in cachexia by microRNAs and long non-coding RNAs. Front. Cell Dev. Biol. 8, 577010 (2020).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Cesana, M. et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell 147, 358–369 (2011).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Mukherjee, S., Banerjee, B., Karasik, D. & Frenkel-Morgenstern, M. mRNA-lncRNA co-expression network analysis reveals the role of lncRNAs in immune dysfunction during severe SARS-CoV-2 infection. Viruses 13, 402 (2021).

  • Arman, K., Dalloul, Z. & Bozgeyik, E. Emerging role of microRNAs and long non-coding RNAs in COVID-19 with implications to therapeutics. Gene 861, 147232 (2023).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Boehm, I. et al. Neuromuscular junctions are stable in patients with cancer cachexia. J. Clin. Invest. 130, 1461–1465 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Huot, J. R., Pin, F. & Bonetto, A. Muscle weakness caused by cancer and chemotherapy is associated with loss of motor unit connectivity. Am. J. Cancer Res. 11, 2990–3001 (2021).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Sartori, R. et al. Perturbed BMP signaling and denervation promote muscle wasting in cancer cachexia. Sci. Transl. Med. 13, eaay9592 (2021).

  • Webster, J. M., Kempen, L., Hardy, R. S. & Langen, R. C. J. Inflammation and skeletal muscle wasting during cachexia. Front. Physiol. 11, 597675 (2020).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Baazim, H., Antonio-Herrera, L. & Bergthaler, A. The interplay of immunology and cachexia in infection and cancer. Nat. Rev. Immunol. 22, 309–321 (2022).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Lang, C. H. Importance of the innate immune response in skeletal muscle to depsis-induced alterations in protein balance. Shock 59, 214–223 (2023).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Frost, R. A., Nystrom, G. J. & Lang, C. H. Multiple Toll-like receptor ligands induce an IL-6 transcriptional response in skeletal myocytes. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290, R773–R784 (2006).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Olson, B., Diba, P., Korzun, T. & Marks, D. L. Neural mechanisms of cancer cachexia. Cancers 13, 3990 (2021).

  • Burfeind, K. G. et al. Circulating myeloid cells invade the central nervous system to mediate cachexia during pancreatic cancer. eLife 9, e54095 (2020).

  • Dzierlega, K. et al. Activin A-expressing polymorphonuclear myeloid-derived suppressor cells infiltrate skeletal and cardiac muscle and promote cancer cachexia. J. Immunol. 211, 497–507 (2023).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Wang, R. et al. A human skeletal muscle stem/myotube model reveals multiple signaling targets of cancer secretome in skeletal muscle. iScience 26, 106541 (2023).

    Article 
    ADS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Arneson, P. C. & Doles, J. D. Impaired muscle regeneration in cancer-associated cachexia. Trends Cancer 5, 579–582 (2019).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Brzeszczynska, J. et al. Loss of oxidative defense and potential blockade of satellite cell maturation in the skeletal muscle of patients with cancer but not in the healthy elderly. Aging 8, 1690–1702 (2016).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Judge, S. M. et al. Skeletal muscle fibrosis in pancreatic cancer patients with respect to survival. JNCI Cancer Spectr. 2, pky043 (2018).

    Article 
    PubMed 

    Google Scholar 

  • Washington, T. A. et al. Development of skeletal muscle fibrosis in a rodent model of cancer cachexia. Cell Biochem. Funct. 41, 478–489 (2023).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Berriel Diaz, M., Rohm, M. & Herzig, S. Cancer cachexia: multilevel metabolic dysfunction. Nat. Metab. 6, 2222–2245 (2024).

    Article 
    PubMed 

    Google Scholar 

  • Levit, L. A. et al. Ethical framework for including research biopsies in oncology clinical trials: American Society of Clinical Oncology Research Statement. J. Clin. Oncol. 37, 2368–2377 (2019).

    Article 
    PubMed 

    Google Scholar 

  • Gallagher, I. J. et al. Suppression of skeletal muscle turnover in cancer cachexia: evidence from the transcriptome in sequential human muscle biopsies. Clin. Cancer Res. 18, 2817–2827 (2012).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Nosacka, R. L. et al. Distinct cachexia profiles in response to human pancreatic tumours in mouse limb and respiratory muscle. J. Cachexia Sarcopenia Muscle 11, 820–837 (2020).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Terry, E. E. et al. Transcriptional profiling reveals extraordinary diversity among skeletal muscle tissues. eLife 7, e34613 (2018).

  • Babic, A. et al. Adipose tissue and skeletal muscle wasting precede clinical diagnosis of pancreatic cancer. Nat. Commun. 14, 4317 (2023).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Narasimhan, A. et al. Small RNAome profiling from human skeletal muscle: novel miRNAs and their targets associated with cancer cachexia. J. Cachexia Sarcopenia Muscle 8, 405–416 (2017).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Kays, J. K. et al. Three cachexia phenotypes and the impact of fat-only loss on survival in FOLFIRINOX therapy for pancreatic cancer. J. Cachexia Sarcopenia Muscle 9, 673–684 (2018).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Kubrak, C. et al. Quantifying the severity of sarcopenia in patients with cancer of the head and neck. Clin. Nutr. 43, 989–1000 (2024).

    Article 
    PubMed 

    Google Scholar 

  • Derstine, B. A. et al. Skeletal muscle cutoff values for sarcopenia diagnosis using T10 to L5 measurements in a healthy US population. Sci. Rep. 8, 11369 (2018).

    Article 
    ADS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Kozomara, A., Birgaoanu, M. & Griffiths-Jones, S. miRBase: from microRNA sequences to function. Nucleic Acids Res. 47, D155–D162 (2019).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Bouchard-Bourelle, P. et al. snoDB: an interactive database of human snoRNA sequences, abundance and interactions. Nucleic Acids Res. 48, D220–D225 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Piuco, R. & Galante, P. A. F. piRNAdb: a piwi-interacting RNA database. Preprint at bioRxiv https://doi.org/10.1101/2021.09.21.461238 (2021).

  • Chan, P. P. & Lowe, T. M. GtRNAdb 2.0: an expanded database of transfer RNA genes identified in complete and draft genomes. Nucleic Acids Res. 44, D184–D189 (2016).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15, 550 (2014).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Xue, H. et al. Single and combined supplementation of glutamine and n-3 polyunsaturated fatty acids on host tolerance and tumour response to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin (CPT-11)/5-fluorouracil chemotherapy in rats bearing Ward colon tumour. Br. J. Nutr. 102, 434–442 (2009).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Enright, A. J. et al. MicroRNA targets in Drosophila. Genome Biol. 5, R1 (2003).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Karagkouni, D. et al. DIANA-TarBase v8: a decade-long collection of experimentally supported miRNA-gene interactions. Nucleic Acids Res. 46, D239–D245 (2018).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Karagkouni, D. et al. DIANA-LncBase v3: indexing experimentally supported miRNA targets on non-coding transcripts. Nucleic Acids Res. 48, D101–D110 (2020).

    CAS 
    PubMed 

    Google Scholar 

  • Huang, H. Y. et al. miRTarBase 2020: updates to the experimentally validated microRNA–target interaction database. Nucleic Acids Res. 48, D148–D154 (2020).

    ADS 
    CAS 
    PubMed 

    Google Scholar 

  • Li, R. et al. GDCRNATools: an R/Bioconductor package for integrative analysis of lncRNA, miRNA and mRNA data in GDC. Bioinformatics 34, 2515–2517 (2018).

    Article 
    PubMed 

    Google Scholar 

  • Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498–2504 (2003).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Kramer, A., Green, J., Pollard, J. Jr & Tugendreich, S. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics 30, 523–530 (2014).

    Article 
    PubMed 

    Google Scholar 

  • Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51, D587–D592 (2023).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28, 1947–1951 (2019).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M. & Tanabe, M. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 44, D457–D462 (2016).

    Article 
    CAS 
    PubMed 

    Google Scholar 

Continue Reading

  • Oracle Stock Soars 40% As Earnings Shockwaves Lift 400+ ETFs

    Oracle Stock Soars 40% As Earnings Shockwaves Lift 400+ ETFs

    This article first appeared on GuruFocus.

    Sep 10 Oracle (NYSE:ORCL) stock jumped more than 40% on Wednesday, extending gains from its latest earnings release and creating ripple effects across the exchange-traded fund market.

    The rally highlights Oracle’s growing role as a cornerstone holding on Wall Street. The software giant now appears in 432 ETFs, with combined ownership exceeding 255 million shares. That depth of institutional exposure means Oracle’s move has had an outsized impact on funds with heavy tech allocations.

    Among the ETFs most exposed are iShares Expanded Tech-Software Sector ETF at 9.91% of assets, Pacer Data and Digital Revolution ETF at 9.18%, and First Trust NASDAQ Technology Dividend Index Fund at 8.97%. Other notable funds with large weightings include Janus Henderson Transformational Growth ETF, FT Vest Technology Dividend Target Income ETF, and iShares Texas Equity ETF.

    Oracle’s surge not only bolsters investor sentiment in its own stock but also lifts broader fund performance. With this degree of ETF representation, moves in Oracle are increasingly influencing sector-wide performance for technology investors.

    Continue Reading

  • Paramount appoints Meta executive Dane Glasgow as chief product officer – Reuters

    1. Paramount appoints Meta executive Dane Glasgow as chief product officer  Reuters
    2. Paramount Skydance Hires Meta Exec Dane Glasgow as Chief Product Officer  Variety
    3. Meta executive Dane Glasgow to join Paramount as Chief Product Officer  MarketScreener
    4. Paramount Hires Meta Exec as Chief Product Officer Amid Tech Reinvention  The Hollywood Reporter
    5. Paramount Hires Google And Meta Alum Dane Glasgow As Chief Product Officer  Deadline

    Continue Reading

  • The EU Pharma Package – Key Issues for the Pharma Industry | Publications | Insights & Events

    The EU Pharma Package – Key Issues for the Pharma Industry | Publications | Insights & Events

    The EU is currently working on revision of its main pieces of sector-specific regulation for medicinal products, following adoption of a package of measures by the European Commission in 2023 (the pharma package).

    Revision of the current legislation has been steered by issues that have arisen in recent years, including concerns with antimicrobial resistance and supply chain security, tested to the extreme during the COVID-19 pandemic, where patient access to medicines was a particular concern.

    Background and Need To Develop Current Rules

    The main pieces of EU pharmaceutical legislation for humans have been in place for over 20 years and include EU Directive 2001/83 (the Directive) and Regulation 726/94 (the Regulation).

    In broad terms, in relation to human medicines, the Directive covers most substantive controls on medicines, including definitions and scope, the need and process for authorisations for products and relevant activities; product information, classification, advertising and supply chain control; and pharmacovigilance. The Regulation covers operation of the European Medicines Agency, EU centralised procedures and arrangements for centralised committees, such as that dealing with pharmacovigilance.

    The pharma package aims to revise and replace this legislation alongside other measures that all aim to enhance availability and equitable access to safe, effective and affordable medicines, provide an innovation friendly framework and reduce administrative burden. Security of supply of medicines and incentivising product development are also key aims.

    Where Are We Now and What Are the Important Issues for Industry

    The process for updating the legislation in the pharma package takes time and involves EU institutions and EU members states. Currently, proposals for the revision have been agreed with the EU Council of Ministers (made up of representatives of EU member states) and the Council of Ministers is to begin negotiations with the European Parliament and EU Commission with a view to reaching agreement on the pharma package legislation with the aim that the new legislation is in place over the next couple of years. We focus below on some of the most relevant areas for concern for the pharma sector.

    Competitor Product Authorisations and Data and Market Exclusivity

    One of the main areas of concern for industry has always been the ability to develop, market and protect products from innovators, and how and when competitors may enter these markets as periods of exclusivity expire. These rules naturally impact on the sources of supply of medicines, and how and when multisource markets develop. This relates to the willingness to develop new products, as well as the security of supply that multisource markets give, as evidenced during the COVID-19 pandemic.

    The current rules on data and market exclusivity are contained in Article 10 of the Directive and follow the 8+2+1 rule, where there is eight years’ data exclusivity plus two years’ market exclusivity, that can be extended by a further year where one or more new therapeutic indications are added and bring significant clinical benefit in comparison to existing therapies.

    It is noted that under current rules, the review of an Article 10 marketing authorisation application can begin after eight years, but the product cannot be marketed as a competitor to the innovator until at least 10 years has passed from initial marketing of the innovator’s product.

    The position adopted by the EU Council in ongoing negotiations is to alter this position to continue to provide eight years’ data exclusivity but reduce market exclusivity from two years to one year. In effect, this reduces the 8+2 to 8+1. This market exclusivity would be increased further by a proposal to allow the possibility of an extension of two years to market protection (from nine to 10 years) where certain predefined conditions are met. The latter includes meeting an unmet medical need.

    The initial proposal from the EU Commission was to reduce the current 8+2 period to 6+2 years, and so the EU Council’s position appears as a compromise that will aim to enhance product availability and security of supply, while recognising that the original pharma package proposal reduced the reward available to innovators where significant R&D investments are made.

    The proposed change to innovator product protection is probably viewed as the most significant area for concern by both the innovator, and generic and biosimilar sectors, where early market entry by competitors provides significant losses or rewards.

    Exclusions From Patent Infringement for Studies and Trials is To Expand

    Article 10 of the current Directive also provides an exemption from patent or supplementary protection certificate (SPC) infringement where necessary studies or trials and consequential practical requirements are conducted with a view to abridged applications under Article 10. These measures, akin to the Bolar exemption in the US, have been implemented in EU member states under national patent law and, as such, there is some scope for minor variation between these when implemented.

    However, the pharma package is to include a proposal, agreed by the EU Council, that the exemption be extended to include submissions for procurement tenders as well as regulatory approvals. This is designed to allow earlier market access in the context of pricing approval and health technology assessment procedures that may cause delays under current rules. This would then support earlier market entry by competitor products to the original innovator product market.

    New Obligation To Ensure Sufficient Supply of Medicines

    The current EU legislation provides limited obligations on marketing authorisation holders (MAH) and distributors to ensure appropriate and continued supplies of products, within the limits of their responsibilities. MAHs also have obligations around notifications of supply cessation, permanent and temporary. The existing provisions are fairly vague, and enforcement of these was seen as problematic.

    The pharma package proposal aims to strengthen these types of control on the supply of medicines by providing a new obligation that MAHs ensure sufficient supply of medicines within individual EU member states. It is unclear exactly how this measure will be promulgated or enforced, but it will provide an extra element of uncertainty for those aiming to market products and in considering where they choose to do so, given the global markets in which medicines are manufactured and supplied.

    Other Measures Agreed by the EU Council and Beyond

    In a measure aimed at encouraging the development of new antimicrobials, the EU’s Council of Ministers has proposed the introduction of transferrable exclusivity vouchers that might be used from five years into a regulatory data protection period and to be subject to a revenue cap of €490 million in annual EU sales of the relevant product in the preceding four years.

    This will aim to compensate what is seen as a lack of incentive to industry to develop antimicrobials, where return on investment can be low, especially where such products have low patient populations and are not usually destined for blockbuster status.

    Additionally, while the factors mentioned above highlight changes to the main EU controls on medicinal products, it is noted that the EU is also looking at changes that aim to enhance laws on medicines used in rare diseases (also known as orphan medicinal products) and patent term extension (known as SPCs in the EU), and a broad overview of these proposals is also important to understand.

    The changes raised above are complex and wide-ranging, and it is strongly recommended that participants in the sector monitor and evaluate how these might impact on their business going forward.

    We are able to advise and assist in this; the main contacts for questions on this are Adrian Spooner and Peter Sellar.

    Continue Reading

  • NCSA’s Delta Powers Research into Blood–Brain Barrier Transport

    NCSA’s Delta Powers Research into Blood–Brain Barrier Transport

    Sept. 10, 2025 — There’s an important component to brain health in our heads – a complex, tightly packed barrier that surrounds the brain called the blood-brain barrier (BBB). This powerful protector makes sure nothing harmful, such as toxins, gets into our brains. But there’s a downside – it also makes it hard to deliver much-needed medicines to their targets in the brain.

    Credit: Shutterstock

    Currently, 98% of drug candidates in early phases of the drug industry cannot cross the BBB, creating a significant challenge for the development of treatments for neurological (Alzheimer’s and Parkinson’s diseases), psychiatric (depression, anxiety) and brain cancer diseases. Think of the BBB as a bouncer at a popular nightclub. The bouncer lets in necessary nutrients, like Omega-3 fatty acids, which are essential for brain development and health, because they’re dressed just right. But the brain club is highly exclusive, and the bouncer sees almost everything else as a problem partier, even medicine that could be life-saving.

    Researchers from the Weill Medical College of Cornell University (Weill Cornell Medicine) are working to discover what happens at the BBB and how that bouncer chooses what to let in and what to deny entry. They’ve been able to make great strides in their work due to the powerful resource, Delta, at the National Center for Supercomputing Applications (NCSA).

    Margarida Rosa

    The bouncer analogy is how Margarida Rosa, a doctoral candidate at Weill Cornell Medicine, describes the process of moving molecules past the BBB to laymen to help them understand it better. She’s working with George Khelashvili, Ph.D, an associate professor at the Department of Systems and Computational Biomedicine at Weill Cornell. In the lab, the research team investigates a special protein that acts like a kind of VIP pass through the usually restrictive BBB. This protein is called MFSD2A (Major Facilitator Superfamily Domain 2A). It’s found in the cells lining the blood vessels of the brain within the BBB, and, importantly, it’s what escorts Omega-3 through the barrier. This protein system is of high interest to the team at Weill because if they can figure out how MFSD2A escorts Omega-3, they could apply that knowledge to make it escort specific drug-like molecules past the BBB, making many medicinal treatments much more effective.

    This is where MFSD2A could be the key to getting medicine directly to the brain. Research has shown that MFSD2A can transport more than Omega-3s through the BBB – certain drugs, such as tunicamycin antibiotic, could also be carried through – but the protein won’t carry just any molecule. Rosa and Khelashvili are working to uncover the specific qualities a molecule must possess to be carried by MFSD2A, with the goal of designing small therapeutic drugs that can pass safety through the BBB.

    An illustration showing how medicine would be transported through the Blood Brain Barrier (BBB) via the MFSD2A protein. Credit: George Khelashvili and Margarida Rosa.

    To perform this research, the team utilized research computing to create highly detailed simulations that allowed them to study how MFSD2A operates at an atomic level.

    “I use computer simulations to get a close-up view of how this protein moves molecules into our brain and keeps others out,” said Rosa. “My aim is to find out the important features that make a molecule ‘party-ready’ for the brain. Just like wearing the right outfit might get you into a party, certain features of a molecule, such as size, charge or hydrophobicity, can make it more likely to be transported by MFSD2A.”

    By analyzing these long simulations with advanced computational biophysics and machine learning approaches, the team can train computer models to recognize the differences between molecules that MFSD2A will transport and those it won’t. “Once I figure out these differences,” explained Rosa, “I can then modify the molecules that usually cannot enter the brain by adding features that will make them more likely to be transported. I will ‘dress them up’ in a way that makes MFSD2A want to let them in. Then I can test whether these ‘outfits’ persuade the bouncer (BBB) to let these molecules enter the brain through MFSD2A.”

    These simulations have given the research team a lot of insight into how MFSD2A operates, including which transitions, steps and specific residues are important for transporting Omega-3 through the protein. They used an advanced mathematical framework called a Markov State Model (MSM), together with specialized machine learning (ML) approaches, to track how the protein conformation changes over time and identify the key steps in MFSD2A-mediated transport of nutrients through the BBB. In their published work, these simulations also helped explain how mutations can disrupt MFSD2A’s function. Specifically, MFSD2A’s dysfunction has been linked to serious brain conditions like Alzheimer’s disease, microcephaly (a condition where the brain doesn’t grow properly), brain damage from sepsis and brain bleeding.

    Once the simulation results are analyzed, the team collaborates with experimental researchers at Columbia University and the University of Queensland to test their predictions. “Integrating computational findings with experiment makes this a truly multidisciplinary research strategy, allowing the formulation of mechanistic hypotheses that can be directly tested. This approach deepens our understanding of MFSD2A’s function and lays the groundwork for rational drug discovery targeting MFSD2A during its dysfunction and the blood-brain barrier, in general,” said Rosa.

    More recently, Khelashvili and Rosa have been running simulations to compare a normal functioning protein to one that’s impaired, and in doing so, they’ve discovered that certain ions can block the MFSD2A from transporting effectively by binding to the protein in a specific way. The team is now preparing a paper that builds on these findings, focusing on how lithium – a common treatment for bipolar disorder – inhibits the function of MFSD2A and the molecular mechanism behind this effect. While lithium remains an important therapy, its side effect on MFSD2A may represent an unintended off-target effect. The group also continues to use their methodology to study MFSD2A mutants that alter the transport of Omega-3 across the BBB, including both those that enhance and impair the protein’s ability.

    George Khelashvili

    Khelashvili and Rosa believe that their project will have an impact in a number of areas. Not only are they optimistic that this research will help with the development of drugs that can be delivered directly to the brain via MFSD2A, but they also hope their research into how MFSD2A functions will help other teams research similar lipid transporters.

    “MFSD2A belongs to a small subset of atypical MFS transporters, which, unlike most other members of the superfamily, transport amphipathic lipidic substrates rather than water-soluble molecules. This gave rise to the hypothesis that the lipid transporter members of the superfamily likely function according to a common mechanism that could differ from that proposed – and extensively studied – for the MFS solute carriers. Our project constitutes a unique opportunity to tackle this problem,” said Khelashvili.

    One of the more impactful aspects of this study is that it provides a strong example to inspire other researchers to use a similar approach. “The use of advanced computational methods, such as molecular dynamics simulations, MSMs and ML analyses, combined with validation through biochemical (e.g., single-cell transport assays and scintillation proximity assays) and biophysical (e.g., CryoEM) experiments, represents the forefront of drug discovery technology,” said Rosa. “This highly integrative approach promises to streamline the drug discovery process, offering innovative platforms and insights.”

    “This research supports drug discovery by learning how MFSD2A transports specific molecules, and we aim to create drugs that leverage this mechanism to cross into the brain, potentially improving treatment options for neurological conditions such as Alzheimer’s disease, depression and brain cancer,” said Khelashvili.

    Much of this work would not have been possible without the resources that NCSA can provide. Khelashvili and Rosa used the U.S. National Science Foundation’s ACCESS program to secure time on the Center’s GPU-based supercomputer, Delta.

    “MD simulations are used to model the behavior of atoms and molecules over time, giving very detailed and important information you cannot obtain from experiments. But biologically meaningful events often occur on the microsecond to millisecond scale, well beyond the reach of standard simulation techniques,” said Rosa. “MFSD2A is also a large and complex system (approximately 230,000 atoms when embedded in the membrane and immersed into a solution environment) with rare transport events, requiring access to the latest GPUs, parallel computing infrastructure and enhanced sampling techniques, all available through ACCESS.”

    “Using HPC resources, we achieved sampling on unprecedented time-scales, over 3 milliseconds of cumulative MD trajectories across different MFSD2A constructs, including various conditions and mutants. Analyses of this massive MD data allowed us to extract detailed and statistically robust information about molecular interactions, inhibitory transport-enabling and transport-inhibiting conditions – insights that are critical for understanding the transport mechanism and for informing drug discovery. These simulations were completed in a matter of months using parallel scheduling via Slurm ensemble jobs, which would have taken years on a standard workstation.”

    For those interested in more detailed information about this research, in addition to the forthcoming publication, there are several articles of note that the team has published on this work:

    Structural Basis of Omega-3 Fatty Acid Transport across the Blood–Brain Barrier, Nature

    Substrate Binding-Induced Conformational Transitions in the Omega-3 Fatty Acid Transporter MFSD2A, Nature Communications

    Automated Collective Variable Discovery for MFSD2A Transporter from Molecular Dynamics Simulations, Biophysical Journal

    Source: Megan Meave Johnson, NCSA

    Continue Reading

  • Amplifying antigen-induced cellular responses with proximity labelling

    Amplifying antigen-induced cellular responses with proximity labelling

  • Su, X. et al. Phase separation of signaling molecules promotes T cell receptor signal transduction. Science 352, 595–599 (2016).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Li, M. & Yu, Y. Innate immune receptor clustering and its role in immune regulation. J. Cell Sci. 134, jcs249318 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Velders, M. P. et al. The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas. Br. J. Cancer 78, 478–483 (1998).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Majzner, R. G. et al. Tuning the antigen density requirement for CAR T-cell activity. Cancer Discov. 10, 702–723 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Watanabe, K. et al. Target antigen density governs the efficacy of anti-CD20–CD28–CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells. J. Immunol. 194, 911–920 (2015).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Qin, W., Cho, K. F., Cavanagh, P. E. & Ting, A. Y. Deciphering molecular interactions by proximity labeling. Nat. Methods 18, 133–143 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Xiao, Q., McAtee, C. K. & Su, X. Phase separation in immune signalling. Nat. Rev. Immunol. 22, 188–199 (2022).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Degn, S. E. & Tolar, P. Towards a unifying model for B-cell receptor triggering. Nat. Rev. Immunol. 25, 77–91 (2025).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Manz, B. N., Jackson, B. L., Petit, R. S., Dustin, M. L. & Groves, J. T-cell triggering thresholds are modulated by the number of antigen within individual T-cell receptor clusters. Proc. Natl Acad. Sci. USA 108, 9089–9094 (2011).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Dustin, M. L. & Groves, J. T. Receptor signaling clusters in the immune synapse. Annu. Rev. Biophys. 41, 543–556 (2012).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Albelda, S. M. Tumor antigen heterogeneity: the “elephant in the room” of adoptive T-cell therapy for solid tumors. Cancer Immunol. Res. 8, 2 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Ma, L. et al. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell 186, 3148–3165 (2023).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Nijhof, I. S. et al. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Leukemia 29, 2039–2049 (2015).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Heitzeneder, S. et al. GPC2–CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity. Cancer Cell 40, 53–69 (2022).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Chew, H. Y. et al. Endocytosis inhibition in humans to improve responses to ADCC-mediating antibodies. Cell 180, 895–914 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Zhang, A. Q. et al. Universal redirection of CAR T cells against solid tumours via membrane-inserted ligands for the CAR. Nat. Biomed. Eng. 7, 1113–1128 (2023).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Park, A. K. et al. Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors. Sci. Transl. Med. 12, eaaz1863 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Han, S., Li, J. & Ting, A. Y. Proximity labeling: spatially resolved proteomic mapping for neurobiology. Curr. Opin. Neurobiol. 50, 17–23 (2018).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Li, J. et al. Cell-surface proteomic profiling in the fly brain uncovers wiring regulators. Cell 180, 373–386 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Branon, T. C. et al. Efficient proximity labeling in living cells and organisms with TurboID. Nat. Biotechnol. 36, 880–887 (2018)

    Article 

    Google Scholar 

  • Geri, J. B. et al. Microenvironment mapping via Dexter energy transfer on immune cells. Science 367, 1091–1097 (2020).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Wang, P. et al. Mapping spatial transcriptome with light-activated proximity-dependent RNA labeling. Nat. Chem. Biol. 15, 1110–1119 (2019).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Lin, Z. et al. Multiscale photocatalytic proximity labeling reveals cell surface neighbors on and between cells. Science 385, eadl5763 (2024).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Tay, N. E. S. et al. Targeted activation in localized protein environments via deep red photoredox catalysis. Nat. Chem. 15, 101–109 (2023).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Zhu, H. et al. Tyrosinase-based proximity labeling in living cells and in vivo. J. Am. Chem. Soc. 146, 7515–7523 (2024).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Buksh, B. F. et al. muMap-Red: proximity labeling by red light photocatalysis. J. Am. Chem. Soc. 144, 6154–6162 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Li, X., Lovell, J. F., Yoon, J. & Chen, X. Clinical development and potential of photothermal and photodynamic therapies for cancer. Nat. Rev. Clin. Oncol. 17, 657–674 (2020).

    Article 
    PubMed 

    Google Scholar 

  • Chao, Y. & Liu, Z. Biomaterials tools to modulate the tumour microenvironment in immunotherapy. Nat. Rev. Bioeng. 1, 125–138 (2023).

    Article 
    CAS 

    Google Scholar 

  • Lee, D., Huntoon, K., Lux, J., Kim, B. Y. S. & Jiang, W. Engineering nanomaterial physical characteristics for cancer immunotherapy. Nat. Rev. Bioeng. 1, 499–517 (2023).

    Article 
    CAS 

    Google Scholar 

  • Chen, J., Zhu, Y. & Kaskel, S. Porphyrin-based metal–organic frameworks for biomedical applications. Angew. Chem. Int. Ed. Engl. 60, 5010–5035 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Wang, J. et al. Porphyrinic metal–organic framework PCN-224 nanoparticles for near-infrared-induced attenuation of aggregation and neurotoxicity of Alzheimer’s amyloid-β peptide. ACS Appl. Mater. Interfaces 10, 36615–36621 (2018).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Giuntini, F. et al. Insight into ultrasound-mediated reactive oxygen species generation by various metal–porphyrin complexes. Free Radic. Biol. Med. 121, 190–201 (2018).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Hananya, N., Ye, X., Koren, S. & Muir, T. W. A genetically encoded photoproximity labeling approach for mapping protein territories. Proc. Natl Acad. Sci. USA 120, e2219339120 (2023).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Scaranti, M., Cojocaru, E., Banerjee, S. & Banerji, U. Exploiting the folate receptor α in oncology. Nat. Rev. Clin. Oncol. 17, 349–359 (2020).

    Article 
    PubMed 

    Google Scholar 

  • Morath, I. et al. Differential recruitment of CD44 isoforms by ErbB ligands reveals an involvement of CD44 in breast cancer. Oncogene 37, 1472–1484 (2018).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Heider, K. H., Kuthan, H., Stehle, G. & Munzert, G. CD44v6: a target for antibody-based cancer therapy. Cancer Immunol. Immunother. 53, 567–579 (2004).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Alford, R. et al. Toxicity of organic fluorophores used in molecular imaging: literature review. Mol. Imaging 8, 341–354 (2009).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Erkes, D. A. & Selvan, S. R. Hapten-induced contact hypersensitivity, autoimmune reactions, and tumor regression: plausibility of mediating antitumor immunity. J. Immunol. Res. 2014, 175265 (2014).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Shokat, K. M. & Schultz, P. G. Redirecting the immune response: ligand-mediated immunogenicity. J. Am. Chem. Soc. 113, 1861–1862 (2002).

    Article 

    Google Scholar 

  • Lu, Y. & Low, P. S. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol. Immunother. 51, 153–162 (2002).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Lillemeier, B. F. et al. TCR and Lat are expressed on separate protein islands on T cell membranes and concatenate during activation. Nat. Immunol. 11, 90–96 (2010).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Nimmerjahn, F. & Ravetch, J. V. Fcγ receptors as regulators of immune responses. Nat. Rev. Immunol. 8, 34–47 (2008).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Vaughan, T. J. et al. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat. Biotechnol. 14, 309–314 (1996).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Liao, K. W., Lo, Y. C. & Roffler, S. R. Activation of lymphocytes by anti-CD3 single-chain antibody dimers expressed on the plasma membrane of tumor cells. Gene Ther. 7, 339–347 (2000).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Pfistershammer, K. et al. No evidence for dualism in function and receptors: PD-L2/B7-DC is an inhibitory regulator of human T cell activation. Eur. J. Immunol. 36, 1104–1113 (2006).

  • Chakraborty, A. K. & Weiss, A. Insights into the initiation of TCR signaling. Nat. Immunol. 15, 798–807 (2014).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Polak, R., Zhang, E. T. & Kuo, C. J. Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment. Nat. Rev. Cancer 24, 523–539 (2024).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Voabil, P. et al. An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. Nat. Med. 27, 1250–1261 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Belmontes, B. et al. Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell-cold solid tumors. Sci. Transl. Med. 13, eabd1524 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Godbersen-Palmer, C., Coupet, T. A., Grada, Z., Zhang, S. C. & Sentman, C. L. Toxicity induced by a bispecific T cell-redirecting protein is mediated by both T cells and myeloid cells in immunocompetent mice. J Immunol 204, 2973–2983 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Oslund, R. C. et al. Detection of cell–cell interactions via photocatalytic cell tagging. Nat. Chem. Biol. 18, 850–858 (2022).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Pasqual, G. et al. Monitoring T cell–dendritic cell interactions in vivo by intercellular enzymatic labelling. Nature 553, 496–500 (2018).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Liu, Z. et al. Detecting tumor antigen-specific T cells via interaction-dependent fucosyl-biotinylation. Cell 183, 1117–1133 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Seath, C. P. et al. Tracking chromatin state changes using nanoscale photo-proximity labelling. Nature 616, 574–580 (2023).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Peri, A. et al. The landscape of T cell antigens for cancer immunotherapy. Nat. Cancer 4, 937–954 (2023).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Garcia-Guerrero, E. et al. Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab. Leukemia 35, 201–214 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Kim, M. S. et al. Redirection of genetically engineered CAR-T cells using bifunctional small molecules. J. Am. Chem. Soc. 137, 2832–2835 (2015).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Lee, Y. G. et al. Use of a single CAR T cell and several bispecific adapters facilitates eradication of multiple antigenically different solid tumors. Cancer Res. 79, 387–396 (2019).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Morgan, R. A. et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843–851 (2010).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Riechelmann, H. et al. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol. 44, 823–829 (2008).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Castellarin, M. et al. A rational mouse model to detect on-target, off-tumor CAR T cell toxicity. JCI Insight 5, 175265 (2020).

    Article 

    Google Scholar 

  • Feng, D. et al. Construction of ultrastable porphyrin Zr metal–organic frameworks through linker elimination. J. Am. Chem. Soc. 135, 17105–17110 (2013).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Chen, X. et al. Formulation of metal–organic framework-based drug carriers by controlled coordination of methoxy PEG phosphate: boosting colloidal stability and redispersibility. J. Am. Chem. Soc. 143, 13557–13572 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Lee, H., Dellatore, S. M., Miller, W. M. & Messersmith, P. B. Mussel-inspired surface chemistry for multifunctional coatings. Science 318, 426–430 (2007).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Duan, H. et al. CD146 bound to LCK promotes T cell receptor signaling and antitumor immune responses in mice. J. Clin. Invest. https://doi.org/10.1172/JCI148568 (2021).

  • Su, S. et al. Immune checkpoint inhibition overcomes ADCP-induced immunosuppression by macrophages. Cell 175, 442–457 (2018).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Neal, J. T. et al. Organoid modeling of the tumor immune microenvironment. Cell 175, 1972–1988 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • McGinnis, C. S., Murrow, L. M. & Gartner, Z. J. DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. Cell Syst. 8, 329–337 (2019).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Wu, Y. PATCH v.1. Zenodo https://doi.org/10.5281/zenodo.16674296 (2025).

    • Continue Reading

  • Teams to host Emirates NBA Cup semifinal games beginning in 2026-27

    Teams to host Emirates NBA Cup semifinal games beginning in 2026-27

    Blake Griffin takes you through all the info you need to know as the 2025 Emirates NBA Cup schedule is announced. Catch all the action starting October 31 on Prime.

    NEW YORK — The National Basketball Association announced today that the Emirates NBA Cup Semifinals will be played at the home arena of the higher-seeded team in each conference, beginning with the 2026-27 NBA season.

    Under existing rules that will continue through the 2025-26 NBA season, the Emirates NBA Cup Semifinals and Championship are played at a neutral site (T-Mobile Arena in Las Vegas for the upcoming season). Starting with the Emirates NBA Cup during the 2026-27 NBA season, the Championship will be the only game played at a neutral site.

    Also today, the NBA Board of Governors approved a change to the Coach’s Challenge rules. Beginning with the 2025-26 NBA season, during review following a Coach’s Challenge of an out-of-bounds violation, the Replay Center official, instead of the on-court crew chief, will determine whether a proximate foul should have been called. The adjustment was approved to expedite the replay review process.

    Last season marked the first time that, as part of a Coach’s Challenge to an out-of-bounds violation, NBA referees could determine whether a proximate foul should have been called on the play. The rule required the on-court crew chief to make this determination, but the decision will now be made by the Replay Center official.

    The Coach’s Challenge rule change was unanimously recommended by the NBA Competition Committee and the league office.

    Continue Reading

  • Litton Das addresses run-rate scenario ahead of Hong Kong clash

    Litton Das addresses run-rate scenario ahead of Hong Kong clash

    BAN face Hong Kong in Group B (Image Source: X/@ACCMedia1)

    What’s the story

    Bangladesh captain Litton Das has indicated that while run-rate is a consideration, their primary focus is on winning as they prepare to face Hong Kong in their Asia Cup opener.
    The match will be played at Sheikh Zayed Stadium in Abu Dhabi on Thursday.
    The question of run-rate emerged after Afghanistan beat Hong Kong by 94 runs, a factor that could come into play if three teams end up with the same points in the group stage.
    Here’s more.

    Focus on winning, not run-rate – Litton Das

    Litton stressed on the need to focus on winning rather than worrying about run-rate.
    “If they play good cricket, it will be tough for us to win by a big margin. We will try to give our hundred percent and aim to win the match,” he said in a pre-match press conference on Wednesday.
    The skipper further added that their main target is winning the match and not getting too caught up in future scenarios.

    Bangladesh wary of upset-minded Hong Kong

    Despite being favorites on paper, Bangladesh aren’t taking Hong Kong lightly.
    The memory of their shocking two-wicket defeat to the same team in 2014 T20 World Cup still haunts them.
    Litton said, “First of all, whenever you ask the question to any captain, they will say cricket is uncertain. You have to play your A-game every match.”
    He also downplayed concerns over heat affecting their performance.

    Hong Kong coach Kaushal Silva eyes Bangladesh upset

    Hong Kong head coach Kaushal Silva hasn’t given up hope of an upset against Bangladesh in their second Group B game.
    He admitted that his team didn’t play to their potential against Afghanistan on Tuesday, but stressed the need to move on and reset before facing Bangladesh.
    “It was a great experience for our boys, especially playing under lights against a Test playing nation,” Silva said after the defeat.

    Continue Reading